Wyss Zürich Logo with claim Wyss Zürich Logo with claim
All News

Muvon Therapeutics announces First Patient Enrolled in Phase II Clinical Study

27-10-2022 – Muvon Therapeutics announces First Patient Enrolled in Phase II Clinical Study in Female Patients with Stress Urinary Incontinence using Novel Regenerative Cell Therapy

Wysszurich keyvisual muvon

Muvon Therapeutics AG, an innovative clinical-stage biotechnology company, today announced that the first patient with Stress Urinary Incontinence has been enrolled as part of the planned Phase II clinical trial (SUISSE MPC 2-Study) using its novel proprietary cell therapy platform.

Similar News

Carlos Mora and Lukas Langenegger 01 08-11-2022

hemotune AG recognized as most innovative blood purification company by Frost & Sullivan

hemotune earns Frost & Sullivan’s 2022 Europe Technology Innovation Leadership Award in the blood purification technology market
ZKB Pionier23 MUVON 17-01-2023

MUVON nominated as finalist for the ZKB Pionierpreis Technopark 2023

MUVON is among the twelve startups shortlisted for Pionierpreis, one of the most important innovation awards for start-ups in Switzerland
Nano1 09-02-2023

Nanoflex secures over USD 12 million in Series A funding

Nanoflex Robotics announced that it has achieved an initial USD 12 million in funding which will be used to bring its first-generation system to market and to accelerate the development of new...